The outcomes of transplant for metastatic disease in the early days of liver transplantation were dismal.1 Early recurrence was common and 3-year survival was unusual. These results, coupled with a shortage of cadaveric organs for transplant, led to an abandonment of transplant as a treatment option for colorectal liver metastases. In this issue of JAMA Surgery, Dueland and colleagues2 present data that see this treatment in a new light.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Fong Y. Who Should Undergo Transplant for Metastatic Colorectal Cancer? A Shift in Treatment Paradigm. JAMA Surg. 2021;156(6):557. doi:10.1001/jamasurg.2021.0268
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: